Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Causes & Control
Erschienen in: Cancer Causes & Control 10/2007

01.12.2007 | Original Paper

A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden)

verfasst von: Peter Wallström, Anders Bjartell, Bo Gullberg, Håkan Olsson, Elisabet Wirfält

Erschienen in: Cancer Causes & Control | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

To study the associations between intake of various types of fat and risk of prostate cancer (PCa) in a population-based cohort.

Methods

We have studied 10,564 initially cancer-free men of the Malmö Diet and Cancer cohort, aged 45–73 years. Diet was assessed by a modified diet history method. Cases and clinical characteristics were ascertained via national and regional registry data.

Results

During a mean follow-up of 11.0 years, 817 incidental PCa cases were diagnosed. Out of these, 281 were classified as advanced. There were 202 cases occurring before 65 years of age. After adjustment for age and energy intake, there was no association between intake of any types of fat and risk of PCa, or between fat intake and advanced PCa or PCa occurring in persons aged <65 years. However, we observed positive associations between intakes of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and risk of PCa. After adjustment for multiple confounders, the latter associations were weakened, but the results were otherwise virtually unchanged.

Conclusions

This large study, with high-validity dietary data, does not support an association between intake of total, saturated, or mono-unsaturated fat and PCa risk. The observed associations between EPA/DHA intakes and PCa are difficult to interpret.
Literatur
1.
Delongchamps NB, Singh A, Haas GP (2006) The role of prevalence in the diagnosis of prostate cancer. Cancer Control 13:158–168PubMed
2.
Bostwick DG, Burke HB, Djakiew D et al (2004) Human prostate cancer risk factors. Cancer 101(10 Suppl):2371–2490PubMedCrossRef
3.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRef
4.
Astorg P (2004) Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Cancer Causes Control 15:367–386PubMedCrossRef
5.
Chan JM, Gann PH, Giovannucci EL (2005) Role of diet in prostate cancer development and progression. J Clin Oncol 23:8152–8160PubMedCrossRef
6.
Giovannucci E, Rimm EB, Colditz GA et al (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571–1579PubMedCrossRef
7.
Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskapulos G, Kranidis A (2002) Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 66:467–477PubMedCrossRef
8.
Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ (1994) Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 86:281–286PubMedCrossRef
9.
Godley PA, Campbell MK, Gallagher P, Martinson FEA, Mohler JL, Sandler RS (1996) Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 5:889–895PubMed
10.
Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L (1997) Prediagnostic level of fatty acids in serum phospholipids: Ω-3 and Ω-6 fatty acids and the risk of prostate cancer. Int J Cancer 71:545–551PubMedCrossRef
11.
Veierød MB, Laake P, Thelle DS (1997) Dietary fat intake and risk of prostate cancer:a prospective study of 25,708 Norwegian men. Int J Cancer 73:634–638PubMedCrossRef
12.
Schuurman AG, van den Brandt PA, Dorant E, Brants HAM, Goldbohm RA (1999) Association of energy and fat intake with prostate carcinoma risk. Cancer 86:1019–1027PubMedCrossRef
13.
Männistö S, Pietinen P, Virtanen MJ et al (2003) Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. Cancer Epidemiol Biomarkers Prev 12:1422–1428PubMed
14.
Laaksonen DE, Laukkanen JA, Niskanen L et al (2004) Serum linoleic and total polyunsaturated fatty acids in relation to prostate and other cancers: A population-based cohort study. Int J Cancer 111:444–450PubMedCrossRef
15.
Leitzmann MF, Stampfer MJ, Michaud DS et al (2004) Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 80:204–216PubMed
16.
Schuurman AG, van den Brandt PA, Dorant E, Goldbohm RA (1999) Animal products, calcium and protein and prostate cancer risk in the Netherlands Cohort Study. Br J Cancer 80:1107–1113PubMedCrossRef
17.
Dennis LK, Snetselaar LG, Smith BJ, Stewart RE, Robbins MEC (2004) Problems with the assessment of dietary fat in prostate cancer studies. Am J Epidemiol 160:436–444PubMedCrossRef
18.
Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A (2001) Fatty fish consumption and risk of prostate cancer. Lancet 357:1764–1766PubMedCrossRef
19.
Augustsson K, Michaud DS, Rimm EB et al (2003) A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 12:64–67PubMed
20.
Hedelin M, Chang ET, Wiklund F et al (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120:398–405PubMedCrossRef
21.
Allen NE, Sauvaget C, Roddam AW et al (2004) A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 15:911–920PubMedCrossRef
22.
Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC (2003) A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev 12:1403–1409PubMed
23.
Gong Z, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 15: 1977–1983PubMedCrossRef
24.
Stocks T, Lukanova A, Rinaldi S et al (2007) Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden. Int J Cancer 120:2678–2686PubMedCrossRef
25.
Berglund G, Elmståhl S, Janzon L, Larsson SA (1993) The Malmö Diet and Cancer Study. Design and feasibility. J Intern Med 232:45–51
26.
Manjer J, Carlsson S, Elmståhl S et al (2001) The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10:489–499PubMedCrossRef
27.
Manjer J, Elmståhl S, Janzon L, Berglund G (2002) Invitation to a population-based cohort study: differences between subjects recruited using various strategies. Scand J Publ Health 30:103–112CrossRef
28.
Wirfält E, Mattisson I, Johansson U, Gullberg B, Wallström P, Berglund G (2002) A methodological report from the Malmö Diet and Cancer study: development and evaluation of altered routines in dietary data processing. Nutr J 1:3PubMedCrossRef
29.
Elmståhl S, Riboli E, Lindgärde F, Gullberg B, Saracci R (1996) The Malmö Food Study. The relative validity of a modified diet history method and an extensive food frequency questionnaire for measuring food intake. Eur J Clin Nutr 50:143–151
30.
Riboli E, Elmståhl S, Saracci R, Gullberg B, Lindgärde F (1997) The Malmö Food Study: validity of two dietary assessment methods for measuring nutrient intake. Int J Epidemiol 26 (Suppl 1):S161–S173PubMedCrossRef
31.
Elmståhl S, Gullberg B, Riboli E, Saracci R, Lindgärde F (1996) The reproducibility of a novel diet history method and an extensive food frequency questionnaire. The Malmö Food Study. Eur J Clin Nutr 50:134–142
32.
Sandblom G, Dufmats M, Olsson M, Varenhorst E (2003) Validity of a population-based cancer register in Sweden. Scand J Urol 37:112–119CrossRef
33.
Willett WC, Stampfer MJ (1998) Implications of total energy intake for epidemiologic analyses. In: Willett WC (ed) Nutritional epidemiology. Oxford University Press, New York, pp 273–301
34.
Nelson M, Bingham S (1997) Assessment of food consumption and nutrient intake. In: Margetts BM, Nelson M (eds) Design concepts in nutritional epidemiology. Oxford University Press, Oxford, pp 123–169
35.
Mattisson I, Wirfält E, Andrén Aronsson C et al (2005) Misreporting of energy: prevalence, characteristics of misreporters and influence on observed risk estimates in the Malmö Diet and Cancer cohort. Br J Nutr 94:832–842PubMedCrossRef
36.
World Cancer Research Fund American Institute for Cancer Research (1997) Food, nutrition and the prevention of cancer: a global perspective. American Institute for Cancer Research, Washington
37.
Greenland S, Rothman KJ (1998) Measures of effect and association. In: Rothman KJ, Greenland S (eds) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia, pp 47–64
38.
Terry PD, Terry JB, Rohan TE (2004) Long-chain (n-3) fatty acid intake and risk of cancers of the breast and the prostate: recent epidemiological studies, biological mechanisms, and directions for future research. J Nutr 134:3412S–3420SPubMed
39.
Sjödin A, Hagmar L, Klasson-Wehler E, Björk J, Bergman Å (2000) Influence of the consumption of fatty Baltic Sea fish on plasma levels of halogenated environmental contaminants in Latvian and Swedish men. Environ Health Persp 108:1035–1041CrossRef
40.
Brouwer A, Longnecker MP, Birnbaum LS et al (1999) Characterization of potential endocrine-related health effects at low-dose levels of exposure to PCBs. Environ Health Persp 107 Suppl 4:639–649CrossRef
41.
Ritchie JM, Vial SL, Fuortes LJ et al (2005) Comparison of proposed frameworks for grouping polychlorinated biphenyl congener data applied to a case-control pilot study of prostate cancer. Environ Res 98:104–113PubMedCrossRef
42.
Greenland S, Pearl J, Robins JM (1999) Causal diagrams for epidemiologic research. Epidemiology 10:37–48PubMedCrossRef
43.
Willett WC, Lenart E (1998) Reproducibility and validity of food-frequency questionnaires. In: Willett WC (ed) Nutritional epidemiology. Oxford University Press, New York, pp 101–147
Metadaten
Titel
A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden)
verfasst von
Peter Wallström
Anders Bjartell
Bo Gullberg
Håkan Olsson
Elisabet Wirfält
Publikationsdatum
01.12.2007
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 10/2007
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9050-4

Weitere Artikel der Ausgabe 10/2007

Cancer Causes & Control 10/2007 Zur Ausgabe

Original Paper

Does excess iron play a role in breast carcinogenesis? an unresolved hypothesis

Letter to the Editor

No sex difference observed in the association between intra-uterine growth and risk of childhood acute lymphoblastic leukaemia

Original Paper

Nitrate in public water supplies and the risk of renal cell carcinoma

Original Paper

Chronic lymphocytic leukemia radiogenicity: a systematic review

Original Paper

Boron intake and prostate cancer risk

Letter to the Editor

Author response: no sex difference observed in the association between intra-uterine growth and risk of childhood acute lymphoblastic leukemia

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise